Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 331

1.

Diagnostic value of symptoms in chronic polyneuropathy: the Erasmus Polyneuropathy Symptom Score (E-PSS).

Hanewinckel R, van Oijen M, Taams NE, Merkies ISJ, Notermans NC, Vrancken AFJE, Ikram MA, van Doorn PA.

J Peripher Nerv Syst. 2019 Jun 7. doi: 10.1111/jns.12328. [Epub ahead of print]

PMID:
31172622
2.

Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy.

Bunschoten C, Jacobs BC, Van den Bergh PYK, Cornblath DR, van Doorn PA.

Lancet Neurol. 2019 May 7. pii: S1474-4422(19)30144-9. doi: 10.1016/S1474-4422(19)30144-9. [Epub ahead of print] Review.

PMID:
31076244
3.

Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy.

van Lieverloo GGA, Wieske L, Verhamme C, Vrancken AFJ, van Doorn PA, Michalak Z, Barro C, van Schaik IN, Kuhle J, Eftimov F.

J Peripher Nerv Syst. 2019 Jun;24(2):187-194. doi: 10.1111/jns.12319. Epub 2019 Apr 29.

PMID:
30973667
4.

Efficient design and analysis of randomized controlled trials in rare neurological diseases: An example in Guillain-Barré syndrome.

van Leeuwen N, Walgaard C, van Doorn PA, Jacobs BC, Steyerberg EW, Lingsma HF.

PLoS One. 2019 Feb 20;14(2):e0211404. doi: 10.1371/journal.pone.0211404. eCollection 2019.

5.

IVIg-induced plasmablasts in patients with Guillain-Barré syndrome.

Brem MD, Jacobs BC, van Rijs W, Fokkink WJR, Tio-Gillen AP, Walgaard C, van Doorn PA, IJspeert H, van der Burg M, Huizinga R.

Ann Clin Transl Neurol. 2018 Nov 27;6(1):129-143. doi: 10.1002/acn3.687. eCollection 2019 Jan.

6.

The ACE I/D polymorphism does not explain heterogeneity of natural course and response to enzyme replacement therapy in Pompe disease.

Kuperus E, van der Meijden JC, In 't Groen SLM, Kroos MA, Hoogeveen-Westerveld M, Rizopoulos D, Martinez MYN, Kruijshaar ME, van Doorn PA, van der Beek NAME, van der Ploeg AT, Pijnappel WWMP.

PLoS One. 2018 Dec 7;13(12):e0208854. doi: 10.1371/journal.pone.0208854. eCollection 2018.

7.

Regional variation of Guillain-Barré syndrome.

Doets AY, Verboon C, van den Berg B, Harbo T, Cornblath DR, Willison HJ, Islam Z, Attarian S, Barroso FA, Bateman K, Benedetti L, van den Bergh P, Casasnovas C, Cavaletti G, Chavada G, Claeys KG, Dardiotis E, Davidson A, van Doorn PA, Feasby TE, Galassi G, Gorson KC, Hartung HP, Hsieh ST, Hughes RAC, Illa I, Islam B, Kusunoki S, Kuwabara S, Lehmann HC, Miller JAL, Mohammad QD, Monges S, Nobile Orazio E, Pardo J, Pereon Y, Rinaldi S, Querol L, Reddel SW, Reisin RC, Shahrizaila N, Sindrup SH, Waqar W, Jacobs BC; IGOS Consortium .

Brain. 2018 Oct 1;141(10):2866-2877. doi: 10.1093/brain/awy232.

8.

Clinical, electrophysiological, and cutaneous innervation changes in patients with bortezomib-induced peripheral neuropathy reveal insight into mechanisms of neuropathic pain.

Bechakra M, Nieuwenhoff MD, van Rosmalen J, Groeneveld GJ, Scheltens-de Boer M, Sonneveld P, van Doorn PA, de Zeeuw CI, Jongen JL.

Mol Pain. 2018 Jan-Dec;14:1744806918797042. doi: 10.1177/1744806918797042.

9.

Second IVIg course in Guillain-Barré syndrome patients with poor prognosis (SID-GBS trial): Protocol for a double-blind randomized, placebo-controlled clinical trial.

Walgaard C, Jacobs BC, Lingsma HF, Steyerberg EW, Cornblath DR, van Doorn PA; Dutch GBS Study Group.

J Peripher Nerv Syst. 2018 Dec;23(4):210-215. doi: 10.1111/jns.12286. Epub 2018 Sep 24.

PMID:
30151941
10.

Small volume plasma exchange for Guillain-Barré syndrome in resource-limited settings: a phase II safety and feasibility study.

Islam B, Islam Z, Rahman S, Endtz HP, Vos MC, van der Jagt M, van Doorn PA, Jacobs BC, Mohammad QD.

BMJ Open. 2018 Aug 17;8(8):e022862. doi: 10.1136/bmjopen-2018-022862.

11.

Advances in management of Guillain-Barré syndrome.

Doets AY, Jacobs BC, van Doorn PA.

Curr Opin Neurol. 2018 Oct;31(5):541-550. doi: 10.1097/WCO.0000000000000602. Review.

PMID:
30074496
12.

Enzyme replacement therapy reduces the risk for wheelchair dependency in adult Pompe patients.

van der Meijden JC, Kruijshaar ME, Rizopoulos D, van Doorn PA, van der Beek NAME, van der Ploeg AT.

Orphanet J Rare Dis. 2018 May 22;13(1):82. doi: 10.1186/s13023-018-0824-4.

13.

A randomised, multi-centre phase III study of 3 different doses of intravenous immunoglobulin 10% in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ProCID trial): Study design and protocol.

Cornblath DR, Hartung HP, Katzberg HD, Merkies ISJ, van Doorn PA.

J Peripher Nerv Syst. 2018 Jun;23(2):108-114. doi: 10.1111/jns.12267. Epub 2018 Apr 26.

14.

Imaging of respiratory muscles in neuromuscular disease: A review.

Harlaar L, Ciet P, van der Ploeg AT, Brusse E, van der Beek NAME, Wielopolski PA, de Bruijne M, Tiddens HAWM, van Doorn PA.

Neuromuscul Disord. 2018 Mar;28(3):246-256. doi: 10.1016/j.nmd.2017.11.010. Epub 2017 Nov 24. Review.

PMID:
29398294
15.

Protocol of a dose response trial of IV immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy (DRIP study).

Kuitwaard K, Fokkink WR, Brusse E, Vrancken AFJE, Eftimov F, Notermans NC, van der Kooi AJ, Merkies ISJ, Jacobs BC, van Doorn PA.

J Peripher Nerv Syst. 2018 Mar;23(1):5-10. doi: 10.1111/jns.12244. Epub 2017 Nov 21.

PMID:
29119642
16.

Long-term benefit of enzyme replacement therapy in Pompe disease: A 5-year prospective study.

Kuperus E, Kruijshaar ME, Wens SCA, de Vries JM, Favejee MM, van der Meijden JC, Rizopoulos D, Brusse E, van Doorn PA, van der Ploeg AT, van der Beek NAME.

Neurology. 2017 Dec 5;89(23):2365-2373. doi: 10.1212/WNL.0000000000004711. Epub 2017 Nov 8.

PMID:
29117951
17.

Maintenance IV immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy.

Kuitwaard K, Fokkink WR, Brusse E, Vrancken AFJE, Eftimov F, Notermans NC, van der Kooi AJ, Merkies ISJ, Jacobs BC, van Doorn PA.

J Peripher Nerv Syst. 2017 Dec;22(4):425-432. doi: 10.1111/jns.12242. Epub 2017 Nov 21. Review.

PMID:
29092099
18.

Prediction of disease progression in Miller Fisher and overlap syndromes.

Verboon C, van Berghem H, van Doorn PA, Ruts L, Jacobs BC.

J Peripher Nerv Syst. 2017 Dec;22(4):446-450. doi: 10.1111/jns.12238. Epub 2017 Nov 15.

PMID:
29065229
19.

Small volume plasma exchange for Guillain-Barré syndrome in resource poor settings: a safety and feasibility study.

Islam MB, Islam Z, Rahman S, Endtz HP, Vos MC, van der Jagt M, van Doorn PA, Jacobs BC, Mohammad QD.

Pilot Feasibility Stud. 2017 Sep 29;3:40. doi: 10.1186/s40814-017-0185-0. eCollection 2017.

20.

The reduction of intraepidermal P2X3 nerve fiber density correlates with behavioral hyperalgesia in a rat model of nerve injury-induced pain.

Bechakra M, Schüttenhelm BN, Pederzani T, van Doorn PA, de Zeeuw CI, Jongen JLM.

J Comp Neurol. 2017 Dec 1;525(17):3757-3768. doi: 10.1002/cne.24302. Epub 2017 Aug 30.

PMID:
28815599
21.

Response to Herbert et al.

de Vries JM, Kuperus E, Hoogeveen-Westerveld M, Kroos MA, Wens SCA, Stok M, van der Beek NAME, Kruijshaar ME, Rizopoulos D, van Doorn PA, van der Ploeg AT, Pijnappel WWMP.

Genet Med. 2017 Nov;19(11):1283-1284. doi: 10.1038/gim.2017.49. Epub 2017 Jun 29. No abstract available.

PMID:
28661488
22.

Polyneuropathy relates to impairment in daily activities, worse gait, and fall-related injuries.

Hanewinckel R, Drenthen J, Verlinden VJA, Darweesh SKL, van der Geest JN, Hofman A, van Doorn PA, Ikram MA.

Neurology. 2017 Jul 4;89(1):76-83. doi: 10.1212/WNL.0000000000004067. Epub 2017 May 31.

PMID:
28566544
23.

Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy.

Mahdi-Rogers M, Brassington R, Gunn AA, van Doorn PA, Hughes RA.

Cochrane Database Syst Rev. 2017 May 8;5:CD003280. doi: 10.1002/14651858.CD003280.pub5. Review.

24.

European consensus for starting and stopping enzyme replacement therapy in adult patients with Pompe disease: a 10-year experience.

van der Ploeg AT, Kruijshaar ME, Toscano A, Laforêt P, Angelini C, Lachmann RH, Pascual Pascual SI, Roberts M, Rösler K, Stulnig T, van Doorn PA, Van den Bergh PYK, Vissing J, Schoser B; European Pompe Consortium.

Eur J Neurol. 2017 Jun;24(6):768-e31. doi: 10.1111/ene.13285. Epub 2017 May 6. Review.

PMID:
28477382
25.

High body mass and kidney dysfunction relate to worse nerve function, even in adults without neuropathy.

Hanewinckel R, Ikram MA, Franco OH, Hofman A, Drenthen J, van Doorn PA.

J Peripher Nerv Syst. 2017 Jun;22(2):112-120. doi: 10.1111/jns.12211.

PMID:
28429469
26.

International Guillain-Barré Syndrome Outcome Study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain-Barré syndrome.

Jacobs BC, van den Berg B, Verboon C, Chavada G, Cornblath DR, Gorson KC, Harbo T, Hartung HP, Hughes RAC, Kusunoki S, van Doorn PA, Willison HJ; IGOS Consortium.

J Peripher Nerv Syst. 2017 Jun;22(2):68-76. doi: 10.1111/jns.12209.

PMID:
28406555
27.

Pharmacokinetics and Pharmacodynamics of Intravenous Immunoglobulin G Maintenance Therapy in Chronic Immune-mediated Neuropathies.

Fokkink W, Koch B, Ramakers C, van Doorn PA, van Gelder T, Jacobs BC.

Clin Pharmacol Ther. 2017 Oct;102(4):709-716. doi: 10.1002/cpt.693. Epub 2017 Jun 5.

PMID:
28378901
28.

Guillain-Barré syndrome: surveillance and cost of treatment strategies - Authors' reply.

Willison HJ, Jacobs BC, van Doorn PA.

Lancet. 2017 Jan 21;389(10066):253-254. doi: 10.1016/S0140-6736(17)30055-7. Epub 2017 Jan 20. No abstract available.

PMID:
28118915
29.

Commentary.

Pijnappel WW, van Doorn PA, van der Ploeg AT.

Clin Chem. 2017 Jan;63(1):48. doi: 10.1373/clinchem.2016.265280. No abstract available.

30.

Association of Albumin Levels With Outcome in Intravenous Immunoglobulin-Treated Guillain-Barré Syndrome.

Fokkink WR, Walgaard C, Kuitwaard K, Tio-Gillen AP, van Doorn PA, Jacobs BC.

JAMA Neurol. 2017 Feb 1;74(2):189-196. doi: 10.1001/jamaneurol.2016.4480.

PMID:
28027337
31.

Treatment dilemmas in Guillain-Barré syndrome.

Verboon C, van Doorn PA, Jacobs BC.

J Neurol Neurosurg Psychiatry. 2017 Apr;88(4):346-352. doi: 10.1136/jnnp-2016-314862. Epub 2016 Nov 11. Review.

PMID:
27837102
32.

Corticosteroids for Guillain-Barré syndrome.

Hughes RA, Brassington R, Gunn AA, van Doorn PA.

Cochrane Database Syst Rev. 2016 Oct 24;10:CD001446. Review.

33.

Prevalence of polyneuropathy in the general middle-aged and elderly population.

Hanewinckel R, Drenthen J, van Oijen M, Hofman A, van Doorn PA, Ikram MA.

Neurology. 2016 Nov 1;87(18):1892-1898. Epub 2016 Sep 28.

PMID:
27683845
34.

Metabolic syndrome is related to polyneuropathy and impaired peripheral nerve function: a prospective population-based cohort study.

Hanewinckel R, Drenthen J, Ligthart S, Dehghan A, Franco OH, Hofman A, Ikram MA, van Doorn PA.

J Neurol Neurosurg Psychiatry. 2016 Dec;87(12):1336-1342. doi: 10.1136/jnnp-2016-314171. Epub 2016 Sep 21.

PMID:
27656045
35.

Peripheral neuropathies.

Hanewinckel R, Ikram MA, Van Doorn PA.

Handb Clin Neurol. 2016;138:263-82. doi: 10.1016/B978-0-12-802973-2.00015-X. Review.

PMID:
27637963
36.

Tracheostomy or Not: Prediction of Prolonged Mechanical Ventilation in Guillain-Barré Syndrome.

Walgaard C, Lingsma HF, van Doorn PA, van der Jagt M, Steyerberg EW, Jacobs BC.

Neurocrit Care. 2017 Feb;26(1):6-13. doi: 10.1007/s12028-016-0311-5.

37.

Quantification of Diaphragm Mechanics in Pompe Disease Using Dynamic 3D MRI.

Mogalle K, Perez-Rovira A, Ciet P, Wens SC, van Doorn PA, Tiddens HA, van der Ploeg AT, de Bruijne M.

PLoS One. 2016 Jul 8;11(7):e0158912. doi: 10.1371/journal.pone.0158912. eCollection 2016.

38.

Neonatal Fc receptor promoter gene polymorphism does not predict pharmacokinetics of IVIg or the clinical course of GBS.

Fokkink WJ, Haarman AE, Tio-Gillen AP, van Rijs W, Huizinga R, van Doorn PA, Jacobs BC.

Ann Clin Transl Neurol. 2016 May 17;3(7):547-51. doi: 10.1002/acn3.307. eCollection 2016 Jul. Erratum in: Ann Clin Transl Neurol. 2017 Jan 09;4(1):71.

39.

Pompe disease in adulthood: effects of antibody formation on enzyme replacement therapy.

de Vries JM, Kuperus E, Hoogeveen-Westerveld M, Kroos MA, Wens SC, Stok M, van der Beek NA, Kruijshaar ME, Rizopoulos D, van Doorn PA, van der Ploeg AT, Pijnappel WW.

Genet Med. 2017 Jan;19(1):90-97. doi: 10.1038/gim.2016.70. Epub 2016 Jun 30.

PMID:
27362911
40.

Neuronal endocytosis of anti-ganglioside antibodies: implications for Guillain-Barré syndrome.

van Doorn PA, Jacobs BC.

Brain. 2016 Jun;139(Pt 6):1622-5. doi: 10.1093/brain/aww078. No abstract available.

PMID:
27234059
41.

[Guillain-Barré syndrome following infection with the Zika virus].

van den Berg B, van den Beukel JC, Alsma J, van der Eijk AA, Ruts L, van Doorn PA, Jacobs BC, Simon CC.

Ned Tijdschr Geneeskd. 2016;160:D155. Dutch.

PMID:
27229696
42.

The epidemiology of neuromuscular disorders: Age at onset and gender in the Netherlands.

Deenen JC, van Doorn PA, Faber CG, van der Kooi AJ, Kuks JB, Notermans NC, Visser LH, Horlings CG, Verschuuren JJ, Verbeek AL, van Engelen BG.

Neuromuscul Disord. 2016 Jul;26(7):447-52. doi: 10.1016/j.nmd.2016.04.011. Epub 2016 Apr 21.

PMID:
27212207
43.

Minutes of the European POmpe Consortium (EPOC) Meeting March 27 to 28, 2015, Munich, Germany.

Schoser B, Laforêt P, Kruijshaar ME, Toscano A, van Doorn PA, van der Ploeg AT; European POmpe Consortium (EPOC).

Acta Myol. 2015 Dec;34(2-3):141-3. No abstract available.

44.

Correlation of the patient's reported outcome Inflammatory-RODS with an objective metric in immune-mediated neuropathies.

Draak TH, Gorson KC, Vanhoutte EK, van Nes SI, van Doorn PA, Cornblath DR, van den Berg LH, Faber CG, Merkies IS; PeriNomS Study Group.

Eur J Neurol. 2016 Jul;23(7):1248-53. doi: 10.1111/ene.13025. Epub 2016 Apr 29.

PMID:
27129110
45.

Assessment scales for the diagnosis of polyneuropathy.

Hanewinckel R, Ikram MA, van Doorn PA.

J Peripher Nerv Syst. 2016 Jun;21(2):61-73. doi: 10.1111/jns.12170. Review.

PMID:
26968746
46.

Does ability to walk reflect general functionality in inflammatory neuropathies?

Draak TH, Gorson KC, Vanhoutte EK, van Nes SI, van Doorn PA, Cornblath DR, van den Berg LH, Faber CG, Merkies IS; PeriNomS Study Group.

J Peripher Nerv Syst. 2016 Jun;21(2):74-81. doi: 10.1111/jns.12167.

PMID:
26968437
47.

Guillain-Barré syndrome.

Willison HJ, Jacobs BC, van Doorn PA.

Lancet. 2016 Aug 13;388(10045):717-27. doi: 10.1016/S0140-6736(16)00339-1. Epub 2016 Mar 2. Review.

PMID:
26948435
48.

Cognitive decline in classic infantile Pompe disease: An underacknowledged challenge.

Ebbink BJ, Poelman E, Plug I, Lequin MH, van Doorn PA, Aarsen FK, van der Ploeg AT, van den Hout JM.

Neurology. 2016 Mar 29;86(13):1260-1. doi: 10.1212/WNL.0000000000002523. Epub 2016 Mar 4. No abstract available.

PMID:
26944269
49.

Hospital Admissions, Transfers and Costs of Guillain-Barré Syndrome.

van Leeuwen N, Lingsma HF, Vanrolleghem AM, Sturkenboom MC, van Doorn PA, Steyerberg EW, Jacobs BC.

PLoS One. 2016 Feb 9;11(2):e0143837. doi: 10.1371/journal.pone.0143837. eCollection 2016.

50.

Elevated Plasma Cardiac Troponin T Levels Caused by Skeletal Muscle Damage in Pompe Disease.

Wens SC, Schaaf GJ, Michels M, Kruijshaar ME, van Gestel TJ, In 't Groen S, Pijnenburg J, Dekkers DH, Demmers JA, Verdijk LB, Brusse E, van Schaik RH, van der Ploeg AT, van Doorn PA, Pijnappel WW.

Circ Cardiovasc Genet. 2016 Feb;9(1):6-13. doi: 10.1161/CIRCGENETICS.115.001322. Epub 2016 Jan 19.

PMID:
26787432

Supplemental Content

Loading ...
Support Center